News headlines about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kura Oncology earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.7318513521885 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Kura Oncology (NASDAQ KURA) traded up $0.55 during mid-day trading on Wednesday, reaching $16.60. The company’s stock had a trading volume of 278,700 shares, compared to its average volume of 180,910. Kura Oncology has a 1-year low of $5.78 and a 1-year high of $17.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48. The stock has a market cap of $501.58 and a price-to-earnings ratio of -10.71.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). equities analysts anticipate that Kura Oncology will post -1.52 earnings per share for the current fiscal year.
A number of equities research analysts have issued reports on KURA shares. Cann reiterated a “buy” rating on shares of Kura Oncology in a research note on Wednesday, November 8th. Citigroup increased their price target on Kura Oncology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. Zacks Investment Research lowered Kura Oncology from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. BidaskClub upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, Oppenheimer set a $18.00 price target on Kura Oncology and gave the stock a “buy” rating in a research note on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $18.08.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Kura Oncology (KURA) Share Price” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/17/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-kura-oncology-kura-share-price.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.